Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 5Phase 3 4Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 4Unknown 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Lymphoid 1

Conditions

Prostatic Neoplasms 4Male Urogenital Diseases 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Selenium × Clear all
NCT00744549 2018-02-14

Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Genitourinary

Prostatic Neoplasms, Male Urogenital Diseases

NCT00844792 2017-10-26

Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

University Health Network, Toronto

Phase 2 Completed
48 enrolled
Genitourinary

Prostatic Neoplasms, Male Urogenital Diseases

NCT00669656 2017-04-20

Herbal Therapy for Treatment of Recurrent Prostate Cancer

University of Southern California

Phase 2 Completed
43 enrolled
Genitourinary

Prostatic Neoplasms

NCT00752739 2012-08-15

Selenium in Treating Patients With Prostate Cancer

University of Arizona

Phase 2 Completed
220 enrolled
Genitourinary

Prostatic Neoplasms

NCT00455416 2008-05-21

KLYMF

Oslo University Hospital

Phase 2 Unknown
45 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡